This resistance mechanism provides a strong rationale for combining IL-4 pathway inhibitors with immune checkpoint blockades, with the goal of restoring anti-tumor immunity and improving treatment outcomes, particularly in CD30-positive lymphomas such as mycosis fungoides. Here, IL4 is linked to mycosis fungoides.